RIG
AZN icon

RiverFront Investment Group’s AstraZeneca AZN Stock Holding History

RiverFront Investment Group’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
1,974
+248
+14% +$46.6K ﹤0.01% 338
2026
Q1 		$340K Buy
+1,726
New +$333K 0.01% 309

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

RiverFront Investment Group's AZN Position: Q2 2026 in Review

RiverFront Investment Group increased its AstraZeneca (AZN) stake by 14% in Q2 2026, buying an estimated $46.6K and bringing the position to 1,974 shares worth $374K. The position accounts for ﹤0.01% of the portfolio, ranked #338.

RiverFront Investment Group first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • RiverFront Investment Group held 1,974 shares of AstraZeneca worth $374K as of Q2 2026.
  • RiverFront Investment Group bought 248 AstraZeneca shares in Q2 2026, an estimated $46.6K.
  • AstraZeneca made up ﹤0.01% of RiverFront Investment Group's portfolio in Q2 2026, its #338 holding.
  • RiverFront Investment Group first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on RiverFront Investment Group's 13F filing for Q2 2026, filed 29 Jul 2026.